Summary of project PR000356
This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000356. The data can be accessed directly via it's Project DOI: 10.21228/M81K5Z This work is supported by NIH grant, U2C- DK119886.
See: https://www.metabolomicsworkbench.org/about/howtocite.php
| Project ID: | PR000356 |
| Project DOI: | doi: 10.21228/M81K5Z |
| Project Title: | Transpulmonary metabolomics in pulmonary arterial hypertension |
| Project Summary: | Pulmonary arterial hypertension (PAH) is a progressive and incurable disease characterized by obliteration of the pulmonary arterioles, elevated pulmonary vascular resistance (PVR), and eventual right heart failure and death. Current medical therapy for PAH is aimed at reducing PVR by targeting pathways involved in vasodilation. Pulmonary vasodilators improve functional capacity but do not target the underlying vascular obstruction. Despite multiple approved therapies, median survival after diagnosis is less than five years, indicating that additional therapeutic targets are needed. |
| Institute: | Vanderbilt University |
| Last Name: | Brittain |
| First Name: | Evan |
| Address: | 2525 West End Ave, Suite 300, Nashville TN 37203 |
| Email: | evan.brittain@Vanderbilt.Edu |
| Phone: | (615) 322-2318 |
Summary of all studies in project PR000356
| Study ID | Study Title | Species | Institute | Analysis(* : Contains Untargted data) | Release Date | Version | Samples | Download(* : Contains raw data) |
|---|---|---|---|---|---|---|---|---|
| ST000464 | Transpulmonary metabolomics in pulmonary arterial hypertension | Homo sapiens | University of North Carolina | NMR | 2018-10-10 | 1 | 159 | Uploaded data (81.3M)* |
